I assume Docetaxel had the best result. This being their first combo trial, it would not make sense to take any chances by using a less efficacious drug. Having it be off patent is a big plus. It's an older drug (since it's off patent) and so the safety and dosing parameters would be extremely well known. That's an important consideration too -- you want to be able to have a reasonable idea of what side effects are to be expected from the Docetaxel itself. There must be tons of data about that.
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links